KaloBios is appealing Nasdaq's decision to delist it
Thomson Reuters
KaloBios Pharmaceuticals Inc, which fired its controversial Chief Executive Martin Shkreli earlier this month, said it had requested an appeal of Nasdaq's decision to delist its shares.
The embattled drugmaker said last week it had been notified by Nasdaq that its stock would be delisted using the exchange operator's "discretionary" authority.
A hearing on the appeal has been scheduled for Feb. 25, the company said on Tuesday.
KaloBios on Monday said... Читать дальше...